Drug Trial Radar · NCT07010393
Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study
Last checked: Nov 19, 2026Latest source record: Jun 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
335
Planned (sponsor's estimate)
Start
Jul 1, 2025
Primary completion
Dec 31, 2027
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Fujian Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multicenter registry tests whether genomically matched neoadjuvant therapy (1-4 cycles tailored to BRAF V600E, RET fusion/mutation, isolated TERT mutation, triple-negative BRAF/RET/TERT, or ICI ± TKI) can render locally advanced, initially unresectable-or high-morbidity-thyroid cancers operable. The primary endpoint is conversion-to-surgery; key secondaries are R0/1 margin rate and 12-month event-free survival, with propensity-score weighting correcting cohort imbalances. Findings aim to define a precision-guided neoadjuvant standard for down-staging advanced thyroid tumors.
Conditions
- Thyroid Neoplasms
Interventions
DabrafenibDrug
150 mg orally twice daily; ≤4 × 28-day cycles
TrametinibDrug
2 mg orally once daily; same duration
SelpercatinibDrug
160 mg orally twice daily; ≤4 cycles
PralsetinibDrug
retrospective, 400 mg orally once daily; ≤4 cycles
LenvatinibDrug
24 mg orally once daily; ≤4 cycles
LarotrectinibDrug
Larotrectinib 100 mg orally twice daily, continuous 28-day cycles.
AnlotinibDrug
12 mg orally once daily; 2 weeks on / 1 week off, ≤4 cycles (alternative)
PembrolizumabDrug
200 mg IV infusion every 3 weeks; ≤4 cycles
SintilimabDrug
200 mg IV infusion every 3 weeks; ≤4 cycles
CabozantinibDrug
Cabozantinib 60 mg orally once daily, continuous 28-day cycles.
BemosuzumabDrug
China PD-L1 antibody bemosuzumab 900 mg IV every 2 weeks (14-day cycle).
Conversion SurgeryProcedure
Conversion Surgery if resectable
Primary outcomes
What the sponsor says the trial is designed to measure.
- Real-World Progression-Free Survival (rwPFS)Time frame: Baseline to radiologic/clinical progression or death, whichever occurs first, up to 36 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.